Literature DB >> 16710995

Construction of shRNA targeted to the rat angiotensin II type 1 receptors and its RNAi in cytoplasma.

Chuanshi Xiao1, Ling Qiu, Qiutang Zen.   

Abstract

The expression vector of shRNA targeted to the rat angiotensin II receptor gene was constructed and the efficacy of siRNAs to modulate the expression of target gene in the in vitro cultured mammalian cells was investigated for antihypertensive therapy in spontaneous hypertensive rat (SHR) at post-transcriptional level. The sense and antisense RNA oligonucleotides strands targeting angiotensin II receptor mRNA were synthesized individually according to the sequence of the rat angiotensin II receptor. For preparation of duplexes, sense- and antisense-stranded oligonucleotides were mixed and annealed, and the annealed duplexes were cloned into the pGenesil-1 vector. . The rat glioma cells were transfected with constructed pGenesil-1-shRNA plasmid and scrambled plasmid. The cultured cells were collected at different phases. RT-PCR and Western blot were performed. The AT1 mRNA and protein levels behaved ultimately same. Compared to control after 48 h, AT1 mRNA levels were decreased to 35.5% +/- 3.0%, and the levels reached their lowest point after 72 h (20.7% +/- 4% of control). At 24 and 48 h, AT1 protein was reduced to 46.9% +/- 4. 2% and 36.98% +/- 3.7% respectively compared to control and a maximum reduction was observed after 72 h of incubation (28.1% +/- 4% compared to controls). Plasmid-based shRNA expression systems targeted against the rat angiotensin II receptor gene were generated successfully. The shRNAs with a 22-nt stem and a short loop were cleaved into small interfering dsRNA (siRNA) by the Dicer. The in vitro transcribed siRNA enables the effective silencing of gene expression to the target mRNA and leads to effective inhibition of translation of proteins and will be lay the foundation of application of gene silencing technology to hypertensive rats.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16710995     DOI: 10.1007/bf02828024

Source DB:  PubMed          Journal:  J Huazhong Univ Sci Technolog Med Sci        ISSN: 1672-0733


  8 in total

1.  Characteristics of patients with uncontrolled hypertension in the United States.

Authors:  D J Hyman; V N Pavlik
Journal:  N Engl J Med       Date:  2001-08-16       Impact factor: 91.245

2.  Improved hypertension management and control: results from the health survey for England 1998.

Authors:  P Primatesta; M Brookes; N R Poulter
Journal:  Hypertension       Date:  2001-10       Impact factor: 10.190

3.  Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans.

Authors:  A Fire; S Xu; M K Montgomery; S A Kostas; S E Driver; C C Mello
Journal:  Nature       Date:  1998-02-19       Impact factor: 49.962

Review 4.  Angiotensin receptors: distribution, signalling and function.

Authors:  D T Dinh; A G Frauman; C I Johnston; M E Fabiani
Journal:  Clin Sci (Lond)       Date:  2001-05       Impact factor: 6.124

Review 5.  The sympathetic system and hypertension.

Authors:  M Esler
Journal:  Am J Hypertens       Date:  2000-06       Impact factor: 2.689

6.  Prevalence of hypertension in the US adult population. Results from the Third National Health and Nutrition Examination Survey, 1988-1991.

Authors:  V L Burt; P Whelton; E J Roccella; C Brown; J A Cutler; M Higgins; M J Horan; D Labarthe
Journal:  Hypertension       Date:  1995-03       Impact factor: 10.190

Review 7.  The genetics of essential hypertension.

Authors:  K M O'Shaughnessy
Journal:  Br J Clin Pharmacol       Date:  2001-01       Impact factor: 4.335

8.  Cost of poor blood pressure control in the UK: 62,000 unnecessary deaths per year.

Authors:  F J He; G A MacGregor
Journal:  J Hum Hypertens       Date:  2003-07       Impact factor: 3.012

  8 in total
  1 in total

1.  Influence of silencing soluble epoxide hydrolase with RNA interference on cardiomyocytes apoptosis induced by doxorubicin.

Authors:  Guangsheng Du; Jiagao Lv; Li He; Yexin Ma
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2011-06-14
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.